News >

Liquid Biopsies: Complementary Tool in Detecting Driver Mutations in NSCLC

Caroline Seymour
Published: Wednesday, May 22, 2019

Dr. Sai-Hong Ignatius Ou

Sai-Hong Ignatius Ou, MD, PhD

Liquid biopsies can be used to augment tissue biopsies in non–small cell lung cancer (NSCLC), and in the case of insufficient tumor tissue, serve as the primary method of detecting a potentially actionable driver mutation with a faster turnaround time, explained Sai-Hong I. Ou, MD, PhD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x